

In the format provided by the authors and unedited.


# Cell-type-specific quantification of protein synthesis in vivo

Lorena Hidalgo San **Jose** and Robert A. J. **Signer** <sup>\*</sup>

---

Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.


\*e-mail: [rsigner@ucsd.edu](mailto:rsigner@ucsd.edu)



### Supplementary Figure 1

Comparison between OP-Puro and anti-puromycin antibody mediated detection of protein synthesis within mouse bone marrow cells in vivo.

a, MFI of OP-Puro (black) and Puromycin (blue) in unfractionated bone marrow cells, HSCs, CMPs, GMPs, and MEPs ( $n = 3$  for each method). Background fluorescence has been subtracted from each population. Data represent mean  $\pm$  standard deviation. Statistical significance between methods within each cell type was assessed by Student's t-test; \*\*\* $P < 0.001$ . b, Representative histograms show OP-Puro incorporation (red) and puromycin incorporation (blue) in unfractionated bone marrow cells compared to unfractionated bone marrow cells from a PBS injected control mouse (gray). All procedures in this protocol involving mice were approved by the UC San Diego Institutional Animal Care and Use Committee.



**Supplementary Figure 2**

The SUnSET method cannot be applied to measure protein synthesis *in vivo*.

A representative histogram shows the inability to detect puromycin on the cell surface of unfractionated bone marrow cells (blue). Unfractionated bone marrow cells from a PBS injected control mouse are shown in gray. All procedures in this protocol involving mice were approved by the UC San Diego Institutional Animal Care and Use Committee.

**Supplementary Table 1.** Absolute numbers of each population analyzed in the HSC samples

Sample	Events	Cells (DAPI <sup>+</sup> )	CD150 <sup>+</sup> CD48 <sup>-</sup> Lin <sup>-</sup>	Sca-1 <sup>+</sup> ckit <sup>+</sup> (HSCs)
1	1010438	1002022	793	72
2	1006636	997654	297	102
3	1177230	997191	120	90
4	1001144	995282	105	77
5	1009741	987164	113	77

**Supplementary Table 2.** Absolute numbers of each population analyzed in the CMP/GMP/MEP samples

Sample	Events	Cells (DAPI <sup>+</sup> )	ckit <sup>+</sup> Lin <sup>-</sup> CD127 <sup>-</sup>	ckit <sup>+</sup> Sca-1 <sup>-</sup>	CD34 <sup>+</sup> CD16/32 <sup>-/low</sup> (CMPs)	CD34 <sup>+</sup> CD16/32 <sup>high</sup> (GMPs)	CD34 <sup>-</sup> CD16/32 <sup>-/low</sup> (MEPs)
1	395431	391728	2320	1620	562	799	156
2	393526	378851	2453	1795	633	762	249
3	393846	388581	2766	2004	503	1118	234
4	425000	337415	1832	1346	481	562	199
5	398234	361318	1996	982	262	428	209

**Supplementary Table 3.** Frequencies related to parent (%) of each population analyzed in the HSC samples.

Sample	Events	Cells (DAPI <sup>+</sup> )	CD150 <sup>+</sup> CD48 <sup>-</sup> Lin <sup>-</sup>	Sca-1 <sup>+</sup> ckit <sup>+</sup> (HSCs)
1	83.6	99.2	0.079	9.08
2	80.6	99.1	0.030	34.3
3	85.3	99.3	0.012	75.0
4	83.5	99.4	0.011	73.3
5	83.2	97.8	0.011	68.1

**Supplementary Table 4.** Frequencies related to parent (%) of each population analyzed in the CMP/GMP/MEP samples.

Sample	Events	Cells (DAPI <sup>+</sup> )	ckit <sup>+</sup> Lin <sup>-</sup> CD127 <sup>-</sup>	ckit <sup>+</sup> Sca-1 <sup>-</sup>	CD34 <sup>+</sup> CD16/32 <sup>-/low</sup> (CMPs)	CD34 <sup>+</sup> CD16/32 <sup>high</sup> (GMPs)	CD34 <sup>-</sup> CD16/32 <sup>-/low</sup> (MEPs)
1	85.0	99.1	0.59	69.8	34.7	49.3	9.63
2	83.2	96.3	0.65	73.2	35.3	42.5	13.9
3	85.5	98.7	0.71	72.5	25.1	55.8	11.7
4	82.2	79.5	0.54	73.5	35.7	41.8	14.8
5	82.6	90.7	0.55	49.2	26.7	43.6	21.3